LiDCO Group Plc
01 June 2005


For immediate release                                                1 June 2005

                                LiDCO GROUP PLC

                           ("LiDCO" or "the Company")

                            Positive Data Presented

     A New Application for LiDCO's Minimally Invasive Monitoring System


1 June 2005: LiDCO Group plc (AIM: LID), the cardiovascular monitoring company,
is pleased to announce that positive data was presented at the Society of
Obstetric Anesthesia and Perinatology meeting held in Palm Springs, California,
USA.  Doctors at the Departments of Anesthesiology & Obstetrics and Gynecology,
University of Texas Health Science Center, San Antonio, TX reported that the
LiDCOplus Monitor, used to observe cardiovascular changes during continuous
epidural anesthesia in a patient undergoing caesarean section, was able to
safely maintain cardiac output and blood pressure monitoring where this
otherwise would not have been possible without the use of an invasive catheter.

This department is one of a number of University centers actively investigating
the potential applications of the LiDCO technology to the anesthetic management
of high risk obstetric patients.

Investigator, Dr McGrane, concluded: "We feel that the LiDCO monitoring system
was a safe, effective, minimally invasive alternative which allowed us to avoid
the risks associated with placement of a PA catheter, and through continuous
hemodynamic monitoring allowed implementation of epidural anesthesia with
confidence, thus avoiding the risks of general anesthesia in this parturient."


Dr Terry O'Brien, LiDCO' s Chief Executive, commented:  "This is the first
report of the use of our minimally invasive monitoring in the high risk
obstetric population. We are very encouraged by these early results and
particularly excited that a number of other University centers are investigating
the use of our device to improve care and outcomes in the late stages of high
risk pregnancy and in life threatening conditions such as pre-eclampsia."


For further information please contact:

LiDCO Group Plc
Terry O'Brien (CEO) terry@lidco.com                                020 7749 1500

Hugh McGarel-Groves (FD) hugh.mcgarelgroves@lidco.com
Buchanan Communications
Tim Anderson, Mary-Jane Johnson, James Strong                      020 7466 5000



Notes for Editors

About LiDCO Plc

LiDCO is a UK-based AIM-traded developer, manufacturer and leading supplier of
minimally invasive, computer-based hemodynamic monitoring equipment and
disposables used primarily for the management of critical care and
cardiovascular risk hospital patients. Use of LiDCO's technology has been shown
to significantly reduce the complications (particularly infections) and costs
associated with major surgery.  The technology was invented in the Department of
Applied Physiology based at St Thomas' Hospital, London where the Company
maintains a research base.


The Company's manufacturing facility is in Hoxton, London and its current
products are:
          
     •    LiDCOplus and PulseCO monitors: computer-based platforms for 
          displaying a range of real-time, continuous hemodynamic parameters 
          including cardiac output, oxygen delivery and fluid volume;

     •    LiDCO disposables: used in conjunction with the LiDCOplus Monitor
          accurately determine cardiac output in a minimally-invasive manner.


Distribution Network:

The Company has now achieved registration of its products in 13 markets in
Europe, the USA, Brazil and Japan.  It sells direct to the NHS in the UK, and
through a worldwide network of specialty critical care distributors.



Background to the recently published clinical trial: Better than standard care -
(EGDT) improves outcome in high risk surgery patients:

The results of a major trial at St George's Hospital, London using LiDCO's
minimally invasive monitoring technology were presented during the 25th
International Symposium on Intensive Care and Emergency Medicine in Brussels
(21st to 25th March). The results have revealed the following:

     a)   Savings in the cost of treating patients amounting to an average of 
          £4,000 per patient.  Extrapolated nationally, this would equate to a 
          saving of £500 million per annum for the NHS

     b)   The monetary saving (£248,000) - resulted from 640 hospital days saved 
          for 62 patients, an average of more than 10 bed days per patient

     c)   The savings in cost and hospital days were associated with a 
          significant reduction in medical complications (particularly 
          infections - which were halved) through the use of LiDCO's minimally 
          invasive technology to improve tissue oxygen levels following surgery.


                      This information is provided by RNS
            The company news service from the London Stock Exchange